News

25 Jan 2011
Cellectis bioresearch first to launch revolutionary custom TAL nuclease service
Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), has today announced that it will launch gene specific TAL nucleases...
20 Jan 2011
Cellectis Acquires Exclusive License to TAL Effector Patents from University of Minnesota
Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that...
Copyright 2012 Cellectis
Design & Development by EtonDigital